- $835.58m
- $339.18m
- $7.87m
Annual income statement for Nuvation Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 7.87 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 0.795 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 43.6 | 93.3 | 120 | 99.8 | 601 |
| Operating Profit | -43.6 | -93.3 | -120 | -99.8 | -593 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -41.7 | -86.8 | -104 | -75.8 | -568 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -41.7 | -86.8 | -104 | -75.8 | -568 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -41.7 | -86.8 | -104 | -75.8 | -568 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -64.3 | -86.8 | -104 | -75.8 | -568 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.295 | -0.439 | -0.447 | -0.346 | -0.532 |